Discussions to Include Purchase of All BaroFold's Assets, Issuances of Patents on the Company's Ultra Shear Technology (UST) Platform, Enhancements to the Company's Core Business Segment (Research Products & Services), and a Brief Outlook for FY2018
SOUTH EASTON, MA / ACCESSWIRE / December 18, 2017 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to provide an update on several recent key accomplishments: the acquisition of all assets of BaroFold, the issuance of two patents on the Company's cutting-edge Ultra Shear Technology ("UST") platform, and enhancements made to PBI's core business segment (Research Products & Services). The Company will also offer a brief outlook for the 2018 fiscal year.
Anyone interested may listen to the teleconference either live (by telephone) or through a replay approximately one day after the call (by telephone or via a link on the Company's website). The replay will be available for at least 30 days thereafter.
All five officers of PBI will be on the call, as will PBI's Chairman Jeffrey N. Peterson and BaroFold's former Chairman, Kyle Lefkoff.
The teleconference will include short presentations by the PBI officers as well as comments by our invited guests. Following the remarks, attendees are invited to participate in a question & answer period.
Date: Wednesday, December 20, 2017 - Time: 4:30 PM Eastern Standard Time (EST)
To attend this teleconference live by telephone:
Dial-in: (877) 407-8031 (North America); (201) 689-8031 (International). Verbal Passcode (for the operator): Pressure BioSciences Business Update.
For those unable to participate in the live teleconference, a replay will be available beginning Thursday, December 21, 2017. The replay will be accessible both by telephone and through the Company's website for at least 30 days.
Replay Numbers: (877) 481-4010 (North America) & (919) 882-2331 (Int'l). Replay ID Number: 23207.
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or "PCT") hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. Our primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, bio-therapeutics characterization, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities are emerging for PBI in (i) the use of our recently acquired PreEMT technology to allow immediate entry into the biologics contract research services sector, and (ii) the use of our recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology ("UST") to create stable nanoemulsions of otherwise immiscible fluids (such as oils and water, fluoropolymers and alcohol, etc.), and to prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies.
For more information about PBI and this press release, please click on the following link:
http://www.pressurebiosciences.com
Please visit us on Facebook, LinkedIn, and Twitter.
Investor Contacts:
Richard T. Schumacher, President & CEO
(T) 508-230-1828
SOURCE: Pressure BioSciences, Inc.